Mora-Buch R, Tomás-Marín M, Pasamar H, Enrich E, Peña-Gómez C, Rudilla F
BK Virus-Specific T Cell Response Associated with HLA Genotypes, RhD Status, and CMV or EBV Serostatus in Healthy Donors for Optimized Cell Therapy
J CLIN IMMUNOL. 2025 Jun 19;45(1):109
DOI: 10.1007/s10875-025-01901-2
IF: IF 5.7
RESEARCH GROUPS
Transfusional Medicine
10
Number of publications
40.00
%
% Q1
10.00
%
% D1
90.00
%
% Leadership
66.67
%
% Female Leadership
1.05
CROWN (2021-2025)
8.16
%
HCP10% (2021-2025)
90.00
%
% Open access
30.00
%
% International Collaboration
0
Highly cited papers / HCP 1% (2021-2025)
1
Publications in high-IF journals with high Altmetric scores
2
Number of Ongoing Projectes (total)
0
International ongoing projects
0
Number of New projects (total)
0
International new projects
0
Number of Active clinical Trials
0
Number of New Clinical Trials
0
Number of Theses
The Transfusion Medicine Group advanced translational research in immunohematology, coagulopathies, cell therapy, and blood safety in 2025. Key achievements included progress in in vitro red blood cell production and the clinical evaluation of umbilical cord blood–derived erythrocytes, supporting novel transfusion strategies. Advanced next-generation sequencing (NGS) and integrative approaches improved the diagnosis of inherited bleeding disorders and enhanced HLA characterization and donor registries. The group also developed high-throughput T-cell receptor profiling and expanded T-cell–based immunotherapies. In parallel, it strengthened surveillance of transfusion-transmitted infections. The group’s contributions to peer-reviewed publications, national networks, and competitive projects further boosted innovation and clinical translation, consolidating its role as a leading center in precision transfusion medicine.
CORE/MISSIONS
PROGRAMS
TEAM
Group Leader
Francisco Vidal Pérez
Principal Investigator (PI)
Ana Belén Alvarez Palomo,Irene Corrales Insa, Joaquim Delgadillo Duarte,Núria Nogués Gálvez, Dinara Samarkanova
Researchers
Mercè Albert Bayo, Eva Alonso Nogués, Sofia Alonso Mateos, Gemma Aran Canals, Julia Ayats Blanch, Carmen Azqueta Molluna, Marta Bes Maijo, Nina Borràs Agustí, Maria Cristina Caparros Felipe, Marc Castells Gómez, NereaCastillo Flores, Laia Closa Gil, Margarita Codinach Creus,Emma Enrich Rande, Andrea Espasa Pérez,Elisenda Farssac Busquets, Jesús Fernandez Sojo,Iris Garcia Martínez, Cecilia González Santesteban, María José Herrero Mata, Carlos Hobeich Naya, Sergio Huertas Torres,Carlos Julia Figueras, Mònica Linares Alberich, Laura Martin Fernandez, Núria Martinez Llonch, Laura Medina Boronat, Eulàlia Miquel Serra, Rut Mora Buch, Maria Piron, Vanessa Pleguezuelos Hernandez, Verònica Pons Escoll, Cristina Prat Vidal, Marina Rierola Carrera, Marta Rodríguez Aliberas, Luciano Rodríguez Gómez,Francesc Rudilla Salvador, Mireia Santos Gómez, Sílvia Sauleda Oliveras, Glòria Sòria Guerrero, Sergi Torramadé Moix
PhD Students
Laura Cacho Cirera, Sílvia Torrents Zapata, Elena Valdivia Garcia
Lab Technicians
Neus Boto Ruiz, Natàlia Comes Fernández, Carina Lera Asensio, Lorena Ramirez Orihuela,Angie Rico Blazquez
SELECTED PUBLICATIONS
Ramesh G, Sebestyen Z, Deshantri AK, Punt S, Martinez Sanchez E, Fernandez-Sojo J, Querol S, Hudecek M, Sanges C, Das R, Ballardini A, Eguizabal C, Geerts D, Ghavamzadeh A, Escamilla Gómez V, Juan M, Larsen TS, Lesný P, Lysák D, Müller M, Perpiñá U, de Wilde S, Malard F, Hoogenboom J, Mooyaart J, Ruggeri A, Straetemans T, Kuball J
Current capacity and gaps in viral vector manufacturing: a survey of centers associated with CTIWP of EBMT, NXTGEN-hightech, DARE-NL, T2EVOLVE, and GoCART coalition
BONE MARROW TRANSPLANT. 2025 Dec 17
DOI: 10.1038/s41409-025-02774-0
IF: IF 5.2
Enrich E, Antón-Iborra M, Hobeich C, Mora-Buch R, Lara-de-León AG, Parra-Martínez A, Sánchez B, Vidal F, Soler-Palacin P, Rudilla F
A High-Throughput Sequencing Strategy for Clinical Repertoire Profiling of T Cell Receptor Beta Chain: Development and Reference Values Across Healthy Adults, Paediatrics, and Cord Blood Units
INT J MOL SCI. 2025 Oct 1;26(19):9590
DOI: 10.3390/ijms26199590
IF: IF 4.9
Gómez EM, Enrich E, Nunes JM, Mata MJH, Rudilla F
Analysis of HLA Allelic and Haplotypic Frequencies in a Cohort of Bone Marrow Donors in Catalonia: Impact of Next-Generation Sequencing on Donor Registry Quality
HLA. 2025 Oct;106(4):e70441
DOI: 10.1111/tan.70441. PMID: 41117020
IF: 4.9
Palomero J, Galvao V, Creus I, Lostes J, Aylagas M, Marín-Bayo A, Rotxés M, Sanz M, Lozano-Rabella M, Garcia-Garijo A, Yuste-Estevanez A, Grases D, Díaz-Gómez J, González J, Navarro JF, Gartner JJ, Braña I, Villalobos X, Bayó-Puxan N, Jiménez J, Palazón AN, Muñoz S, Villacampa G, Piris-Giménez A, Barba P, Codinach M, Rodríguez L, Querol S, Muñoz-Couselo E, Tabernero J, Martín-Lluesma S, Gros A, Garralda E
Preclinical data and design of a phase I clinical trial of neoantigen-reactive TILs for advanced epithelial or ICB-resistant solid cancers
IMMUNOONCOL TECHNOL. 2024 Dec 2;25:101030
DOI: 10.1016/j.iotech.2024.101030
IF: 4.82
SELECTED PROJECTS
RICORS TERAV. Technology and therapeutic developments: innovation, transfer to the health system and education
Principal Investigator: Joaquim Vives Armengol
Agency: Carlos III Institute of Health
Funding: 338.472,20 €
Period: 2022 -2025
TERAV+
Principal Investigator: Joaquim Vives Armengol
Agency: Carlos III Institute of Health
Funding: 287.557,71
Period: 2025 – 2027
Investigation of the unresolved molecular etiology of inherited bleeding disorders using advanced molecular tools and data integration systems.
Principal Investigator: Irene Corrales Insa
Agency: Carlos III Institute of Health
Funding: 177.500 €
Period: 2024 – 2026
Translation of an allogeneic tissue-engineered product for the treatment of focal articular cartilage lesions
Principal Investigator: Joaquim Vives Armengol
Agency: Carlos III Institute of Health
Funding: 131.558,46 €
Period: 2023 - 2027
Clinical evaluation of umbilical cord blood red blood cells for transfusion in extremely premature infants
Principal Investigator: Dinara Samarkanova
Agency: Carlos III Institute of Health
Funding: 61.105 €
Period: 2023 - 2025
PATENTS
DISSEMINATION ACTIVITIES
